The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2024 | MRD as a surrogate endpoint for AML therapy
Christopher Hourigan, MD, DPhil, Virginia Tech FBRI Cancer Research Center, Washington, DC, outlines the uses of measurable residual disease (MRD) in acute myeloid leukemia (AML) and highlights its potential as a surrogate endpoint for accelerating regulatory approval in the drug development space. Dr Hourigan discusses some consortiums formed with this goal in mind. This interview took place at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) congress in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
